Nationwide recall of Neocate Infant Specialized Formula, Lot # P91877, due to a manufacturing error that resulted in protein levels lower than that declared on the label.
Continue reading...25. September 2009
Comments Off
Voluntary recall because of potential manufacturing problems.
Continue reading...25. September 2009
Comments Off
Early Communication describing an increased number of adverse events and deaths in patients using Exjade who are over sixty years old who have myelodysplastic syndrome (MDS).
Continue reading...25. September 2009
Comments Off
Cases of acute pancreatitis reported in patients treated with sitagliptin.
Continue reading...24. September 2009
Comments Off
Class I Recall due to possibility of obstruction or disruption of therapy. Posted 09/24/2009
Continue reading...21. September 2009
Comments Off
Nationwide recall due to risk of obstruction and inability to ventilate patient.
Continue reading...17. September 2009
Comments Off
FDA continues to receive reports of progressive multifocal leukoencephalopathy (PML) in patients receiving Tysabri.
Continue reading...16. September 2009
Comments Off
Boxed Warning added to labeling, describing risks of severe tissue injury, including gangrene, following intravenous administration of promethazine.
Continue reading...16. September 2009
Comments Off
Class I recall due to failure or delay in delivery of therapy.
Continue reading...10. September 2009
Comments Off
Class I recall because the device may increase the resistance of the flow of air into the lungs, resulting in ineffective ventilation and the inability to verify the correct placement of a breathing tube when inserting it into the windpipe.
Continue reading...
29. September 2009
Comments Off